Basser Research Center for BRCA


2012-2013 Basser Research Center Grants

Cancer Risk Reduction and Prevention

Minimizing adverse outcomes following RRSO in BRCA1/2 mutation carriers:

Susan Domchek, MD was funded to comprehensively investigate the effect of risk-reducing oophorectomy on a variety of health outcomes. Findings from this study will be helpful in advising patients on the best timing for oophorectomy and in establishing whether interventions to treat side effects are needed.

Comprehensive Evaluation of Cancer Risk Modifiers in BRCA1/2 Mutation Carriers:

Timothy Rebbeck, PhD has been awarded funding to study factors that modify BRCA1/2 cancer risks in carriers to provide information that may aid women and their providers in making optimal decisions about cancer prevention strategies.

Development of Vaccine Targeting the Tumor Vasculature for the Prevention of BRCA-deficient Tumors:

Andrea Facciabene, PhD has been working to study and develop a potential vaccine for BRCA-related cancers that may teach the immune system to react to and destroy cancerous tissue.

Cancer Therapy Targets and Predictors of Therapy Response

Chromatin modifying factors and BRCA1/2:

Roger Greenberg, MD, PhD has been funded to study other DNA errors present in BRCA-related cancers to determine if these errors predict response to certain therapies, towards the end of developing better chemotherapy approaches based on the specific genetic changes in BRCA-related cancers.

Interferon-related DNA damage resistance signature (IRDS) in BRCA mutant tumor:

Andrew Minn, MD, PhD had been funded to study changes in the DNA of BRCA-related tumors to evaluate whether these DNA changes predict response to chemo- and radiation therapies in order to determine optimal treatment strategies.

Whole genome sequencing of breast and ovarian cancers associated with BRCA1/2 mutations:

Kate Nathanson, MD, has been funded to sequence the DNA of breast and ovarian tumors for BRCA1/2 carriers to understand the molecular changes that may represent new targets for treatment or predict drug sensitivity or resistance to current regimens.

Early Detection

Development of molecular imaging of tumor vasculature for the early detection of hereditary ovarian and breast cancer:

Drs. George Coukos and Chungsheng Li investigate innovative molecular imaging techniques that visualize the tiny veins that grow to feed cancers which could lead to better methods for early detection of BRCA-related cancers.

Blood-borne biomarkers of dysplasia and early cancer in patients with BRCA mutations:

Dr. Rhim's laboratory recently found that cells from the pancreas (and other organs) can enter the bloodstream when a pre-cancerous lesion is present but long before a tumor has formed. Dr. Rhim's work focuses on applying this discovery to develop a screening method for detecting BRCA-related cancers early.

Communication and Risk Assessment

REACH: Research to evaluate adolescents and early communication of hereditary risk

Dr. Angela Bradbury was awarded Basser funding to study communication about hereditary cancer risk within families, with a focus on adolescents. Her work aims to inform interventions that increase preventative behaviors and minimize adverse psychological outcomes in adolescents and young adults from BRCA families.



Jordan Center Rena Rowan Breast Center MacDonald Womens Cancer Risk Cell & Vaccine Production Ovarian Cancer Research Breast Cancer Research Program Center for Personalized Medicine Translational Research Program BRC 4 BRCA